Navigation Links
Blood protein may hold key to stopping tumor growth in cancer patients

WINSTON-SALEM, N.C. A recent discovery by researchers at Wake Forest University School of Medicine could clear the way for a new drug that inhibits tumor growth in cancer patients and could potentially help in the healing of wounds.

The discovery stems from a study, recently published in the Proceedings of the National Academy of Sciences of the United States of America, in which researchers looked at angiogenesis the body's formation of new blood vessels from existing blood vessels and how some blood proteins are involved in that process and affect blood vessel growth.

Researchers found that a protein called ferritin binds to and cripples the ability of another blood protein, called HKa, to shut down blood vessel growth. Because new blood vessels supply a steady stream of nutrients and oxygen that are essential for tumor growth, researchers found that the binding of the two proteins actually assists in new blood vessel formation by removing HKa's influence and therefore promotes tumor growth.

The finding led researchers to the hypothesis that if they can somehow prevent the binding of ferritin and HKa, it will allow HKa to prevent new blood vessel growth and therefore block the growth of tumors.

The finding also has possible implications for wound care. In order to heal, wounds need blood vessel growth. It is therefore possible that by increasing the binding of ferritin to HKa, one could increase the rate at which a serious wound heals.

"It's been known for a long time that levels of ferritin are increased in people with tumors, but it's never been understood why that happens," said Suzy V. Torti, Ph.D., the study's lead investigator, an associate professor of biochemistry and an expert in iron biology at the School of Medicine. "Ferritin appears to play an important role in blood vessel formation. Further, the interaction between ferritin and HKa may represent a new area of interest for possible drug development."

For the study, researchers injected mice with prostate cancer cells to determine how ferritin and HKa affected the formation of new blood vessels.

The mice injected with the cancer cells grew tumors. But when researchers mixed HKa with the tumor cells, the HKa inhibited blood vessel formation. When researchers added ferritin to the mixture of HKa and cancer cells, however, the ferritin restored blood vessel formation, allowing the tumors to grow again.

"Blood vessels can either be helpful, for example in wound healing, or they can be harmful, for example by favoring tumor growth," Torti said. "Our new finding is that the interaction between ferritin and HKa can influence blood vessel formation. This finding could serve as the basis for strategies to either inhibit or stimulate blood vessels. This opens up a new realm of potential ways to treat tumors or other conditions that depend on new blood vessel formation."

The research team, supported by a National Institutes of Health grant, has begun work to develop an anti-tumor drug based on their findings.

Lan G. Coffman, Ph.D., Derek Parsonage, Ph.D., Ralph D'Agostino Jr., Ph.D., and Frank M. Torti, M.D., M.P.H, all of the Wake Forest University School of Medicine, also collaborated on the study.


Contact: Jessica Guenzel
Wake Forest University Baptist Medical Center

Related medicine news :

1. Effort Could Lead to Blood Tests for Heart Problems
2. Blood test for brain injuries gains momentum
3. After heart attack, bone marrow stem cells increase blood flow within heart
4. Statin Might Help Fight Blood Clots in Veins
5. Video: CRESTOR(R) Reduced Risk of Blood Clots in the Veins
6. LegalView Informs Baxter Heparin Patients of New Testing Standards for Blood Thinner Following Deaths From Previous Contamination
7. Kidney Ailments May Rise Along With Blood Pressure
8. Cord Blood America Applauds Congressional Effort Supporting Cord Blood Storage
9. Cord Blood Registry Supports Family Cord Blood Banking Act
10. Researchers decipher blood stem cell attachment, communication
11. Cord Blood America Announces Results of Shareholder Special Meeting
Post Your Comments:
(Date:11/26/2015)... ... 26, 2015 , ... Jobs in hospital medical laboratories and in the imaging ... staffing agency Aureus Medical Group . These fields, as well as ... searching for healthcare jobs through the company’s website, , The leading ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... has collaborated with Women’s Web – an online resource for Indian women ... mental and emotional well-being relationship, life balance, stress, professional development, and lifestyle. ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season ... and pleasing the palates of attendees is of the utmost importance. Whether you ... seasonal get-together, give these recipes a try this holiday season. , Turkey Croquettes ...
(Date:11/25/2015)... Vegas, NV (PRWEB) , ... November 25, 2015 , ... ... invites patients to learn more about hair loss treatment with the Capillus272™ Pro laser ... an effective solution for thicker and fuller hair, without the need for surgery, prescription ...
(Date:11/25/2015)... CA (PRWEB) , ... November 25, 2015 , ... According ... Vinci surgical robot is being more and more widely heralded as a breakthrough for ... da Vinci method has over traditional laparoscopic surgery is that it can greatly reduce ...
Breaking Medicine News(10 mins):
(Date:11/25/2015)... Israel , November 25, 2015 ... KTOV ) (TASE: KTOV), a biopharmaceutical company focused ... treatment of various clinical conditions, today announced the closing ... American Depository Shares ( ADSs ), each representing 20 ... up to 3,158,900 ADSs. The ADSs and warrants were ...
(Date:11/25/2015)... , Nov. 25, 2015  Trovagene, Inc. (NASDAQ: ... today announced that Chief Executive Officer Antonius Schuh, Ph.D., ... 27 th Annual Piper Jaffray Healthcare Conference. ... the New York Palace Hotel in New ... 1:30 p.m. EST. Mr. Schuh will be available for ...
(Date:11/25/2015)... Nov. 25, 2015 Allergan plc (NYSE: ... and Rugen Therapeutics, a start-up  biotechnology company focused ... CNS disorders and funded by the F-Prime Biomedical ... entered into an exclusive collaboration to support the ... Spectrum Disorders (ASD) and Obsessive Compulsive disorders (OCD). ...
Breaking Medicine Technology: